This trial tested autologous TILs plus IL-2 in patients with stage 2, 3a, or 3b NSCLC deemed to have potentially resectable disease and reported encouraging results among the subset of patients with stage 3b disease. The gene discussed is IL2; the disease is non-small cell lung carcinoma.